3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
27
Fallopian Tube Neoplasms
9
Prostatic Neoplasms
8
Breast Neoplasms
8
Neoplasms
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Mesothelioma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Recurrence
2
Mesothelioma, Malignant
2
Melanoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Interventions
durvalumab
5
Nivolumab
3
Cyclophosphamide
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
padeliporfin
2
anlotinib
2
Trabectedin
2
Sunitinib
2
Pemetrexed
2
Docetaxel
2
Chemoradiotherapy
2
Carboplatin
2
Bevacizumab
2
sotorasib
1
relatlimab
1
relacorilant
1
pembrolizumab
1
patritumab
1
palbociclib
1
olaparib
1
niraparib
1
nintedanib
1
montanide ISA 51
1
golotimod
1
genexol-PM
1
ceralasertib
1
cemiplimab
1
camrelizumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms by Site
×
niraparib
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled